Trending...
- PLP ANNOUNCES ACQUISITION OF PILOT PLASTICS ASSETS
- Dental Tourism is on the Rise and This Dental Hygienist is Providing the Consultations
- L-Strategies political and business consulting firm launched by partners Angie Wong and Jared Craig with Donna and Stan Fitzgerald
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 29, 2022, Navidea and its majority-owned subsidiary Macrophage Therapeutics, Inc. filed an appeal of the judgment by the District Court of Harris County, Texas in Case No. 2018-24442-151; Capital Royalty Partners II, L.P. et al. v. Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics, Inc., with the 14th Court of Appeals of Texas for review by the appellate court.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company's pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.
More on Ohio Pen
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http://www.sec.gov or at http://ir.navidea.com.
More on Ohio Pen
Investors are urged to consider statements that include the words "will," "may," "could," "should," "plan," "continue," "designed," "goal," "forecast," "future," "believe," "intend," "expect," "anticipate," "estimate," "project," and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
Contacts
Navidea Biopharmaceuticals, Inc.
Jeffrey Smith
Vice President of Operations
614-822-2365
jsmith@navidea.com
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company's pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.
More on Ohio Pen
- Lineus Medical® Awarded ISO 13485 and MDSAP Certifications
- Captain D's Sails into 2023 with Full Slate of New Restaurants Under Construction
- Saturated Market Creates Golden Opportunity for Florida Luxury Custom Home Builder to the Stars!
- Well-Being and Equity (WE ) In The World Mobilizes Change for a More Economically and Racially Just Society
- A+ Expands "In Person" ACT Tutoring Services in Greater Cincinnati Ohio
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http://www.sec.gov or at http://ir.navidea.com.
More on Ohio Pen
- Maximize Your Profit: Tips from Collectors Coins & Jewelry on Selling Gold Jewelry Safely and Effectively
- MPE Partners Announces Two Senior Team Promotions
- City of Akron Public Art Commission Issues Request for Proposal to Create Electronic Database of Art in Akron
- Entrinsik Board Announces New CEO
- Sweethearts sends 'sweet-and-desist' to Big Tech over 'like' button
Investors are urged to consider statements that include the words "will," "may," "could," "should," "plan," "continue," "designed," "goal," "forecast," "future," "believe," "intend," "expect," "anticipate," "estimate," "project," and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
Contacts
Navidea Biopharmaceuticals, Inc.
Jeffrey Smith
Vice President of Operations
614-822-2365
jsmith@navidea.com
Filed Under: Business
0 Comments
Latest on Ohio Pen
- Texas Automotive Lift & Equipment Distributor chooses Employees Ownership
- Civista Bancshares, Inc. Declares First Quarter Common Dividend
- TWO PUBLIC ALLIES ALUMNI JOIN THE NATIONAL BOARD OF DIRECTORS
- SurePoint Technologies Recognized as Legal Technology Trailblazer by The National Law Journal
- Louisville Riverport Authority Applies To Include South Central Kentucky In Foreign Trade Zone #29 Service Area
- Westfield Completes Acquisition of Lloyd's of London Syndicate 1200
- PLP ANNOUNCES ACQUISITION OF PILOT PLASTICS ASSETS
- IntellaTriage Hires New Director of Clinical Operations
- Armada Power and Leap Announce Partnership to Expand Access to California Energy Markets
- Metro Commercial brokers deal for BJ's Wholesale Club in West Palm Beach, FL
- L-Strategies political and business consulting firm launched by partners Angie Wong and Jared Craig with Donna and Stan Fitzgerald
- Zilker Partners Expands Recruiting and Digital Marketing Services to Keep Pace with Changing Business Climate
- Dental Tourism is on the Rise and This Dental Hygienist is Providing the Consultations
- Bio-Oil® Celebrates Body Confidence Through Body Positivity Month Campaign
- Advanced Drainage Systems Announces Quarterly Cash Dividend
- New Book Launches to Bestseller Status--Answers the Question "Why Is It So Hard to Find Quality Workers?"
- Acquisition of NDT Classroom Bolsters NDT Training Portfolio
- Fifth Third Bank to Increase Prime Lending Rate to 7.75%
- Cascade Asset Management Recognized in 2023 Gartner® Market Guide for IT Asset Disposition Report
- '23 is the Year of the Podcast Radio Play